UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...

Presenter 1: When the words get tricky, phonics get all sticky, blending them together doesn't work the same. You can see that all tricky words don't look the way they should be heard. Presenter 2: ...